Current state of art for transplantation paradigms in peripheral T-cell lymphomas

Expert Review of Hematology

Volumn 6, Issue 4, 2013, Pages 465-474

  Perrone, Giulia ^a   Farina, Lucia ^a   Corradini, Paolo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

allogeneic stem cell transplantation; autologous stem cell transplantation; graft versus lymphoma; peripheral T cell lymphoma

Indexed keywords

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84894180839     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.814437     Document Type: Review

References (63)

1. Petrich AM, Helenowski I, Galamaga RW, Nabhan C. Trends in incidence and outcome in T-cell lymphoma since 1992: a SEER database analysis. Blood 120(121), 1 (2012).
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26(25), 4124-4130 (2008).
3. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92(1), 76-82 (1998).
4. Falini B, Pileri S, Zinzani Pl et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93(8), 2697-2706 (1999).
5. Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann. Oncol. 1(1), 45-50 (1990).
6. Mounier N, Simon D, Haioun C, Gaulard P, Gisselbrecht C. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J. Clin. Oncol. 20(5), 1426-1427 (2002).
7. Simon A, Peoch M, Casassus P et al. Upfront VIP-reinforced-ABVD (VIPrABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized Phase III trial GOELAMS-LTP95. Br. J. Haematol. 151(2), 159-166 (2010).
8. Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7), 2316-2323 (2007).
9. Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103(8), 2920-2924 (2004).
10. Kim Jg, Sohn Sk, Chae Ys et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a Phase II study. Cancer Chemother. Pharmacol. 60(1), 129-134 (2007).
11. Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116(18), 3418-3425 (2010).
12. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 333(23), 1540-1545 (1995).
13. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J. Clin. Oncol. 18(16), 3025-3030 (2000).
14. Gisselbrecht C, Lepage E, Molina T et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J. Clin. Oncol. 20(10), 2472-2479 (2002).
15. Mounier N, Gisselbrecht C, Briere J et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann. Oncol. 15(12), 1790-1797 (2004).
16. Corradini P, Tarella C, Zallio F et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20(9), 1533-1538 (2006).
17. Rodriguez J, Conde E, Gutierrez A et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur. J. Haematol. 79(1), 32-38 (2007).
18. Mercadal S, Briones J, Xicoy B et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann. Oncol. 19(5), 958-963 (2008).
19. Reimer P, Rudiger T, Geissinger E et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol. 27(1), 106-113 (2009).
20. D'amore F, Relander T, Lauritzsen Gf et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J. Clin. Oncol. 30(25), 3093-3099 (2012).
21. Rodriguez J, Conde E, Gutierrez A et al. The adjusted international prognostic index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 92(8), 1067-1074 (2007).
22. Yang Dh, Kim Ws, Kim Sj et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol. Blood Marrow Transplant. 15(1), 118-125 (2009).
23. Numata A, Miyamoto T, Ohno Y et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 45(2), 311-316 (2010).
24. Chen Ai, Mcmillan A, Negrin Rs, Horning Sj, Laport Gg. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol. Blood Marrow Transplant. 14(7), 741-747 (2008).
25. Feyler S, Prince Hm, Pearce R et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 40(5), 443-450 (2007).
26. Rodriguez J, Conde E, Gutierrez A et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann. Oncol. 18(4), 652-657 (2007).
27. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7), 2474-2479 (2004).
28. Song Kw, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br. J. Haematol. 120(6), 978-985 (2003).
29. Kewalramani T, Zelenetz Ad, Teruya-Feldstein J et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br. J. Haematol. 134(2), 202-207 (2006).
30. Blystad Ak, Enblad G, Kvaloy S et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 27(7), 711-716 (2001).
31. Jantunen E, Wiklund T, Juvonen E et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 33(4), 405-410 (2004).
32. Federico M, Rudiger T, Bellei M et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J. Clin. Oncol. 31(2), 240-246 (2013).
33. Kyriakou C, Canals C, Goldstone A et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 26(2), 218-224 (2008).
34. Sieniawski M, Angamuthu N, Boyd K et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 115(18), 3664-3670 (2010).
35. Dhedin N, Giraudier S, Gaulard P et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br. J. Haematol. 107(1), 154-161 (1999).
36. Kim Sw, Tanimoto Te, Hirabayashi N et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 108(1), 382-389 (2006).
37. Le Gouill S, Milpied N, Buzyn A et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J. Clin. Oncol. 26(14), 2264-2271 (2008).
38. Rodriguez R, Nademanee A, Ruel N et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol. Blood Marrow Transplant. 12(12), 1326-1334 (2006).
39. Goldberg Jd, Chou Jf, Horwitz S et al. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk. Lymphoma 53(6), 1124-1129 (2012).
40. Corradini P, Dodero A, Zallio F et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J. Clin. Oncol. 22(11), 2172-2176 (2004).
41. Faulkner RD, Craddock C, Byrne JL et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 103(2), 428-434 (2004).
42. Wulf Gg, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant. 36(3), 271-273 (2005).
43. Shustov Ar, Gooley Ta, Sandmaier Bm et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br. J. Haematol. 150(2), 170-178 (2010).
44. Zain J, Palmer JM, Delioukina M et al. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk. Lymphoma 52(8), 1463-1473 (2011).
45. Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant. 47(1), 65-72 (2012).
46. Dodero A, Spina F, Narni F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26(3), 520-526 (2012).
47. Corradini PV, Rambaldi A, Miceli R, Patriarca F, Gallamini A. Intensified chemo-immunotherapy including up-front autologous or allogeneic stem cell transplantation (SCT) for young patients with newly diagnosed peripheral T-cell lymphomas: final results of a Phase II multicenter prospective clinical trial. Blood Abstract(120), 1984 (2012).
48. Rodriguez J, Munsell M, Yazji S et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J. Clin. Oncol. 19(17), 3766-3770 (2001).
49. Barrett Aj, Savani Bn. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20(10), 1661-1672 (2006).
50. Suzuki R, Suzumiya J, Nakamura S et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 37(4), 425-431 (2006).
51. Izutsu K, Kanda Y, Ohno H et al. Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program. Blood 103(5), 1955-1960 (2004).
52. Kyriakou C, Canals C, Finke J et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J. Clin. Oncol. 27(24), 3951-3958 (2009).
53. Ennishi D, Maeda Y, Fujii N et al. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. Leuk. Lymphoma 52(7), 1255-1261 (2011).
54. Lin Hn, Liu Cy, Pai Jt et al. How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models? Blood Cancer J. 2, e93 (2012).
55. Younes A, Bartlett Nl, Leonard Jp et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812-1821 (2010).
56. Casulo CZ, Moskowitz C, Horwitz S. Negative interim FDG-PET scan is predictive of superior outcome in T cell lymphoma. Blood 114(22), 1956 (2009).
57. Kim MK, Kim S, Lee SS et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann. Hematol. 86(6), 435-442 (2007).
58. O'connor Oa, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin. Oncol. 29(9), 1182-1189 (2011).
59. Coiffier B, Pro B, Prince Hm et al. Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30(6), 631-636 (2012).
60. Damaj G, Bouabdallah K. Preliminary results from an open-label, multicentric, Phase II study of bendamustine in relapsed or refractory T-cell lymphoma from the French GOELAMS group: the BENTLY trial. Ann. Oncol. 22(4), 125 (2011).
61. Yamamoto K, Utsunomiya A, Tobinai K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28(9), 1591-1598 (2010).
62. Qi W, Spier C, Liu X et al. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk. Res. 37(4), 434-439 (2013).
63. Dreyling M, Thieblemont C, Gallamini A et al. ESMO consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann. Oncol. 24(4), 857-877 (2013).